Strategies to Improve the Potency of Oxazolidinones towards Bacterial Biofilms
Open Access
- 13 April 2022
- journal article
- review article
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (11) , e202200201
Abstract
Biofilms are part of the natural lifecycle of bacteria and are known to cause chronic infections that are difficult to treat. Most antibiotics are developed and tested against bacteria in the planktonic state and are ineffective against bacterial biofilms. The oxazolidinones, including the last resort drug linezolid, are one of the main classes of synthetic antibiotics progressed to clinical use in the last 50 years. They have a unique mechanism of action and only develop low levels of resistance in the clinical setting. With the aim of providing insight into strategies to design more potent antibiotic compounds with activity against bacterial biofilms, we review the biofilm activity of clinically approved oxazolidinones and report on structural modifications to oxazolidinones and their delivery systems which lead to enhanced anti‐biofilm activity.Keywords
Funding Information
- Australian Research Council (FT140100746, DP210101317)
This publication has 192 references indexed in Scilit:
- Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage StudyAntimicrobial Agents and Chemotherapy, 2011
- Inhibition of Staphylococcus epidermidis Biofilm Formation by Rabbit Polyclonal Antibodies against the SesC ProteinInfection and Immunity, 2009
- Infection Associated with Prosthetic JointsNew England Journal of Medicine, 2009
- In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial AgentAntimicrobial Agents and Chemotherapy, 2009
- Systemic Antimicrobial Therapy in OsteomyelitisSeminars in Plastic Surgery, 2009
- Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with RibosomesAntimicrobial Agents and Chemotherapy, 2009
- Biomaterial technology for tissue engineering applicationsJournal of The Royal Society Interface, 2009
- Oritavancin Kills Stationary-Phase and BiofilmStaphylococcus aureusCells In VitroAntimicrobial Agents and Chemotherapy, 2009
- Human Host Defense Peptide LL-37 Prevents Bacterial Biofilm FormationInfection and Immunity, 2008
- In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community PathogensAntimicrobial Agents and Chemotherapy, 2008